On the morning of 15 July 2025, China Medical System Holdings Limited ("CMS" or the "Group") rang the...

The board of directors of China Medical System Holdings Limited (the "Company", together with its subsidiaries

In February 11th 2025, with a Corporate Sustainability Assessment (CSA) score of 61, surpassing 93% of global peers, China...

China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or...

China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or...

On 6 December, China Medical System Holdings Limited ("CMS" or the "Group") is pleased to announce that...

China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or...

China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or...

CMS enters the "New Product Era" driven by exclusive and innovative products, with exclusive and innovative drugs revenue accounts for over 56%.

China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or...

In July 2024, China Medical System Holdings Limited ("CMS" or the "Group") has once again been recognized...

On June 25, China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group"

China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or...

China Medical System Holdings Limited ("CMS" or the "Group") is pleased to announce that on 22 April...

Povorcitinib, a selective oral JAK1 inhibitor discovered by Incyte, is an investigational medicine being evaluated for the treatment of non-segmental vitiligo, hidradenitis suppurativa (HS), prurigo nodularis (PN), asthma and chronic spontaneous urticaria

On March 27, 2024, China Medical System ("CMS" or the "Company") released its 2023 annual results. The...

China Medical System Holdings Limited ("CMS" or the "Group") is pleased to announce that on 2 February...

On 29 December, 2023, PharmaGend Global Medical Services Pte. Ltd. ("PharmaGend"), jointly invested by China Medical...

China Medical System Holdings Limited is pleased to announce that according to a notice issued by National Healthcare Security...